Evidence map›Paper›PMID 29552044›Full record

ArticleIranian journal of pharmaceutical research : IJPR2017

Maryam Ghadiri, Ebrahim Vasheghani-Farahani, Fatemeh Atyabi, Farzad Kobarfard, Hossein Hosseinkhani

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Nanocarriers for anticancer drugs: Challenges and perspectives.Saudi journal of biological sciences · 2022
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maryam GhadiriBiomedical Engineering Division, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran.
Ebrahim Vasheghani-FarahaniBiomedical Engineering Division, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran.
Fatemeh AtyabiNanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Farzad KobarfardDepartment of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein HosseinkhaniInnovation Center for Advanced Technology, Matrix, Inc., New York 10029, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cationic polymeric nanoparticles have great potential for developing drug delivery systems with limited side effects for tumor medication. The goal of this research is investigation of cationic dextran-spermine polymer (DS) efficacy for improvement of hydrophilic drug delivery to negatively charged cancerous cells. Capecitabine (as a hydrophilic antineoplastic drug) was loaded into the magnetic dextran-spermine nanoparticles (DS-NPs) via ionic gelation. Design of experiments was applied to specify how the significant factors affect size, surface charge and capecitabine entrapment efficiency of the DS-NPs. Physicochemical properties,

Indexed as

CancerControlled releaseDrug delivery systemsFactorial designU87MG

Identifiers

PMID29552044
PMCPMC5843296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.